Search fresh public links, source activity, and post angles for Daiichi Sankyo.
Fresh curated links around Daiichi Sankyo are collected here so marketers can spot useful updates and turn timely ideas into posts faster.
Recent items include:
Recent curated links from global sources. Generate one free draft from any story, then use SocialBu to schedule and refine your content calendar.
The Japanese drugmaker aims to more than double oncology revenue to above ¥2.3 trillion by 2030 and become one of the world's top five oncology players by 2035.
Daiichi Sankyo aims to transform its antibody-drug conjugate leadership into a top global oncology standing. In a new five-year business plan unveiled Monday, the Japanese pharma o...
Sang Anonymous (not verified) Thu, 05/07/2026 - 02:21 field_thread_url https://cafepharma.com/boards/threads/sang.673523/ board name...
Datroway landed its third FDA approval in the past 18 months, this time as a treatment for triple negative breast cancer. The antibody drug conjugate was developed under a broad co...
Twenty patients who took Tavneos, a drug for blood vessel inflammation, later died after developing liver dysfunction.
A little over a year after reabsorbing its anticoagulant abelacimab, Novartis has now terminated two phase 3 trials for the antibody.
Pharmacies and wholesalers claimed Takeda Pharmaceutical delayed generic competition from entering the market, forcing them to overpay for a gastrointestinal drug. Takeda said the...
Twenty people in Japan died after taking Tavneos, though it's unclear whether the drug killed those people, a media report said.
The agreement includes Lilly’s new pill Foundayo and restores coverage for Zepbound, erasing what had been a commercial edge for rival Novo Nordisk.
Takeda has ended development of its nausea and vomiting drug candidate for strategic reasons, continuing its multi-year struggles in the therapeutic area.
Takeda has terminated a neuro partnership with Denali Therapeutics as the Japanese pharma undergoes a massive restructuring marked by significant layoffs.
Pfizer and Israeli generic drugmaker Dexcel on Friday agreed to drop a case Pfizer brought to block Dexcel from creating a generic version of the heart medication Vyndamax.
Samsung Bioepis announced Wednesday the launch of its Ustekinumab biosimilar in Japan, marking the company’s first product debut in the country under a partnership with NIPRO Corp....
Trung Huynh, an analyst with RBC Capital Markets, has projected Foundayo will reach peak-year sales of $36 billion—14% above the $31.68 billion racked up by last year’s best sellin...
Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.